secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K/A
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001104659-24-071514
Event type: other
Sentiment:  negative
Materiality: 0.65
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting
--------------------------------------------------------------------------------

- Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
- All four director nominees elected: Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet.
- Stock plan amendment approved: 526,212 for, 205,773 against, 4,853 abstain.
- Auditor WithumSmith+Brown ratified: 2,193,452 for, 159,569 against, 39,556 abstain.
- Adjournment proposal passed but no adjournment motion made.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924071514/0001104659-24-071514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924071514/tm2417255d2_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer